Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Exact Sciences

10/05/2021 | 05:32pm EST


© MT Newswires 2021
All news about EXACT SCIENCES CORPORATION
12/03EXACT SCIENCES : Going the Extra Mile
PU
12/02Exact Sciences Corp. Announces Data from the Rx for Positive Node, Endocrine Responsive..
CI
12/01Publication in The New England Journal of Medicine Confirms that Tens of Thousands of W..
PR
11/30EXACT SCIENCES : Presentation
PU
11/29Exact Sciences Corporation and Pfizer Inc. Enter into an Amendment to the Amended & Res..
CI
11/23Exact Sciences Says New Data in Clinically Low-Risk Prostate Cancer Patients Backs Use ..
MT
11/23New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predicto..
PR
11/23Exact Sciences Corporation Announces Publication of Results Underscoring the Importance..
CI
11/18Exact Sciences Partners With Jefferson Health on Multi-Cancer Earlier Detection Test Re..
MT
11/18Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Dete..
PR
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 735 M - -
Net income 2021 -520 M - -
Net Debt 2021 1 330 M - -
P/E ratio 2021 -25,2x
Yield 2021 -
Capitalization 13 198 M 13 198 M -
EV / Sales 2021 8,37x
EV / Sales 2022 7,35x
Nbr of Employees 4 900
Free-Float 99,3%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | EXAS | US30063P1057 | MarketScreener
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 76,59 $
Average target price 129,35 $
Spread / Average Target 68,9%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
EXACT SCIENCES CORPORATION-39.19%13 198
GUARDANT HEALTH, INC.-24.22%9 220
BGI GENOMICS CO., LTD.-28.68%5 894
ADAPTIVE BIOTECHNOLOGIES CORPORATION-55.64%3 579
INVITAE CORPORATION-64.15%3 393
SEEGENE, INC.-31.09%2 910